Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

DONGSUNG PHARMACEUTICAL CO.,LTD

동성제약002210KOSPISector: Pharma & Biotech
₩1,4800.87%Market cap ₩143.0BAs of Sep 1, 2026 close · updated once daily
Market cap
₩143.0B
#521 in KOSPI
Loss
PER not computable
6.12x
Sector median 1.61x
0.0%
Sector median 0.0%
F
Grade F19.7 ptsBottom 4% of 2,523 graded stocksMethodology v2.0
Financial strength
17.2/100
Growth momentum
19.5/100
Price attractiveness
19.9/100
Shareholder Return
37.5/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCDFCurrent

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band F with a total score of 19.7 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩1,458High ₩1,946
Latest close
Price change by period
1W
0.30%
1M
19.80%
3M
23.90%
1Y
23.90%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

17.2/100
How much debt does it carry relative to equity?
620.7%
Sector median 51.6%
Sector lowhighBottom 3% in sector
Can it cover what's due within a year?
68.5%
Sector median 191.7%
Sector lowhighBottom 14.4% in sector
How much of revenue becomes profit?
-11.6%
Sector median -2.4%
Sector lowhighBottom 43.6% in sector
How much did it earn on its own capital?
-110.1%
Sector median -4.5%
Sector lowhighBottom 7.9% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

19.5/100
How much did revenue grow in a year?
-1.4%
Sector median 6.4%
Sector lowhighBottom 30.7% in sector
Has it grown steadily over three years?
-2.3%
Sector median 4.9%
Sector lowhighBottom 26.6% in sector
Did core profits grow in a year?
-76.5%
Sector median 3.6%
Sector lowhighBottom 12.2% in sector
Are core profits higher than three years ago?
-226.7%
Sector median 3.5%
Sector lowhighBottom 8.3% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

19.9/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 17.2% in sector
Is the price expensive relative to book value?
6.12x
Sector median 1.61x
Sector lowhighBottom 22.5% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
2,211,148 shares (8.3% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 1 met · 8 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩25.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩12.9B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-12.7% → -18.3%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩12.9B vs -₩25.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
68.7% → 86.1%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
73.9% → 68.5%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
26,100,970 → 26,619,507
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-6.5% → -11.6%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.77x → 0.62x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026F

Methodology version change (v2.0 applied)

Jul 15, 2026FVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 70,000,000 new shares, equal to 263.0% of shares outstanding before the increase (filed 2026-04-22). View filing ↗

Private CB/BW issuance resolutions (past 36 months)

2 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-04-03). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

2 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2026-04-03). View filing ↗

CEO (representative executive officer) change filings (past 36 months)

4 CEO (representative executive officer) change filings were submitted in the past 36 months (latest filing 2026-04-15). View filing ↗

Management-dispute lawsuit filing

A filing under the KRX form “소송등의제기ㆍ신청(경영권분쟁소송)” (filing/petition of lawsuit — management dispute) was received (received 2026-03-19). View filing ↗

Largest-shareholder changes (past 36 months)

The largest shareholder changed 2 times in the past 36 months (latest change 2025-06-27, per annual report).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Embezzlement/breach-of-trust allegationJun 23, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗
Capital reductionMay 14, 2026Source ↗

View in the filings calendar →